Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
This Week in Addiction Medicine is an audio summary of the recent top stories and research articles from the field of addiction medicine. Intended to serve as an accompaniment to the ASAM Weekly newsletter or as a stand-alone resource, This Week covers recent publications in addiction medicine research.
Tuesday Feb 07, 2023
Tuesday Feb 07, 2023
Tuesday Feb 07, 2023
Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015–2020
Pediatrics
Opioid related overdose among adolescents and young adults in the United States is rising. Medications for opioid use disorder (MOUD), including buprenorphine, can reduce the risk of overdose; however, they are underutilized. Given rates of opioid use disorder (OUD) among youth, these findings suggest that many young people who could benefit from MOUD are not receiving it. Pediatricians could play a role in expanding access to MOUD for this high-risk population. Efforts to expand access to MOUD for adolescents could include improving pediatrician training in OUD treatment and encouraging all clinicians who care for adolescents and young adults to prescribe buprenorphine for MOUD.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jan 31, 2023
Tuesday Jan 31, 2023
Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic
JAMA Network Open
Questions remain about emergency authorizations permitting telehealth services for buprenorphine, and whether these measures resulted in overdose deaths involving buprenorphine. This cross-sectional study examined 74,474 opioid-involved overdose deaths in 46 states and the District of Columbia prior to and during COVID-19. From July 2019-June 2021 there was a total of 89,111 total overdose deaths and 74,474 opioid-involved overdose deaths; buprenorphine was involved in 1,955 deaths, 2.2% of all drug overdose deaths and 2.6% of opioid-involved overdose deaths. Of these, a higher proportion were female, non-Hispanic White, and lived in rural areas. While opioid-involved overdose deaths increased during this period, those involving buprenorphine did not increase.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jan 24, 2023
Tuesday Jan 24, 2023
Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
Health & Justice
This study investigated OUD best practices in US jails in those counties heavily impacted by overdose. Core best practice domains included screening, clinical assessment by qualified treatment provider, medically managed withdrawal, medication for opioid use disorder (MOUD) administration, services for pregnant women, counseling/wrap-around services, collaboration with community MOUD providers, assistance with Medicaid/insurance coverage, re-entry services, and overdose prevention. Some 92% reported some MOUD availability, but only 20% provided it to persons assessed with OUD. Best practices were more common in counties with larger populations, a higher percentage of Hispanic residents, fewer people living below the poverty line, and fewer jail admissions. A number of challenges including MOUD funding, training, and addressing stigma were reported. This study highlights the impact of lost opportunities for reducing disease, death, and recidivism that result from the lack of greater MOUD availability and accessibility.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jan 17, 2023
Tuesday Jan 17, 2023
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use
JAMA Oncology
This prospective cohort study investigated whether postsurgical acute pain using a restrictive opioid prescription protocol (ROPP) of 3 days or less after discharge would result in reduced opioid use. Mean opioid prescribing days decreased from a mean (SD) of 3.9 (4.5) days in the pre-ROPP group to 1.9 (3.6) days in the post-ROPP group (P
Tuesday Jan 10, 2023
Tuesday Jan 10, 2023
A neuromarker for drug and food craving distinguishes drug users from non-users
Nature Neuroscience
Functional MRI images were obtained while subjects were exposed to visual cues for drugs and palatable foods and asked to rate their level of craving. Subjects were individuals who use drugs (cigarette users=21, alcohol users=17, and cocaine users n=21) and matched controls (n=40). Machine learning was used to identify a pattern of neural activation associated with craving, the Neurobiological Craving Signature (NCS), that extended throughout the brain including areas such as the parietal and temporal areas and cerebellum, not usually associated with craving. The same NCS was found for food and drugs indicating the similarity of these cravings. NCS response to drug cues was able to identify individuals who use drugs with an 82% accuracy. The authors suggest that the NCS has promise for diagnosing SUD as well as measuring responses to treatment.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jan 03, 2023
Tuesday Jan 03, 2023
The ASAM Weekly's most read news items from 2022 were as follows:
On ‘Last Week Tonight,’ John Oliver Takes on the Nation’s Dumbest Drug Myth
Rolling Stone
High-dose drug treats fentanyl overdose, if you can get it
New Haven Register
A man who lost 80 pounds on a 'game changer' weight-loss drug also lost his desire to drink alcohol. Experts say the drug could be a treatment for addiction.
MSN/Insider
The Next Big Addiction Treatment
The New York Times
What Is Delta-8, and Why Is It So Popular?
The New York Times
Can a monthly injection be the key to curbing addiction? These experts say yes
Los Angeles Times
They Call It ‘Tranq’ — And It’s Making Street Drugs Even More Dangerous
KHN
Medication for Drinking Addiction May Thwart Liver Disease
MedPage Today
The Most Important Question About Addiction
The New York Times
Gabapentin's link to fatal drug overdoses draws concern
UPI News
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Dec 27, 2022
Tuesday Dec 27, 2022
Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition
The American Journal of Psychiatry
The authors present a newly developed National Institute on Alcohol Abuse and Alcoholism (NIAAA) definition of recovery from the DSM-5 diagnosis of alcohol use disorder (AUD). This definition views recovery as a process of behavioral change and an outcome, incorporating two key components of recovery: remission from DSM-5 AUD and cessation from heavy drinking, a non-abstinent recovery outcome. It also emphasizes the importance of biopsychosocial functioning and quality of life in enhancing outcomes. By adopting a uniform definition, researchers and health care professionals can more precisely operationalize and measure recovery-related processes.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Dec 20, 2022
Tuesday Dec 20, 2022
Tuesday Dec 20, 2022
Genetic diversity fuels gene discovery for tobacco and alcohol use
Nature
This study leverages global genetic diversity across 3.4 million individuals from four major clines of global ancestry to power the discovery and fine-mapping of genomic loci associated with tobacco and alcohol use, to inform function of these loci via ancestry-aware transcriptome-wide association studies, and to evaluate the genetic architecture and predictive power of polygenic risk within and across populations. The authors found that increases in sample size and genetic diversity improved locus identification and fine-mapping resolution, and that a large majority of the associated variants showed consistent effect sizes across ancestry dimensions. However, polygenic risk scores developed in one ancestry performed poorly in others, highlighting the continued need to increase sample sizes of diverse ancestries to realize any potential benefit of polygenic prediction.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Dec 13, 2022
Tuesday Dec 13, 2022
Tuesday Dec 13, 2022
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
The New England Journal of Medicine
This cohort study involving pregnant persons in the US from 2000-2018 found that buprenorphine treatment for opioid use disorder during pregnancy was associated with more favorable neonatal outcomes than methadone treatment. Neonatal abstinence syndrome occurred in 69% of the infants exposed to methadone as compared with 52% of those exposed to buprenorphine in the 30 days before delivery. An inverse association was also observed between buprenorphine exposure (as compared with methadone exposure) and preterm birth, regardless of whether exposure occurred in early or late pregnancy in both the unadjusted and adjusted analyses. Inverse associations were also observed between buprenorphine exposure (as compared with methadone exposure) and small size for gestational age and low birth weight.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Dec 06, 2022
Tuesday Dec 06, 2022
Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products
Heart Rhythm
This study investigated the cardiovascular effects of exposure to tobacco smoke, vape aerosol, heated tobacco products, marijuana smoke, THC free marijuana, or air (placebo control). Rats were exposed to a single 5 minute session 5 days a week for 2 months. This exposure was judged to be similar to a single smoking or vaping session a day. Left ventricular dilation and reduction in LV ejection fraction was seen in all non-air groups along with reduction in heart rate variability. Both atrial fibrillation and ventricular tachycardia were more easily induced in all non-air groups. Decrease in microvessel density and severe interstitial fibrosis was seen on histology from all non-air groups. The authors conclude that all tobacco products (including vaping) and marijuana carry substantial risk of cardiac disease.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

ASAM, founded in 1954, is a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine.
ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction.
Visit www.ASAM.org for more information.
Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
Disclaimer:
This podcast is for informational purposes only and should not be considered health advice.
• We are not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.
• This podcast is not intended to replace professional medical advice.
• The views expressed in this podcast may not be those of the host or the management.